Pancreatic Cancer Research

ResearcherHôpital BeaujonActive in the last 2 years

Petr Kavan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6836-8333; OpenAlex author ID A5010372361. Sources: ClinicalTrials.gov.

Their work

Papers
12 (first author 1, last author 0)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: 1 trial · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper, 1 trial · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 12

  1. A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer. First author DOI 10.1007/s00262-026-04307-0↗
  2. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarc… Co-author DOI 10.1038/s41467-026-70120-z↗
  3. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  4. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  5. Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use. Co-author DOI 10.3390/curroncol32030128↗
  6. Feasibility and safety of endoscopic ultrasound-guided diffusing alpha emitter radiation therapy for advanced pancreatic cancer: Preliminary data. Co-author DOI 10.1055/a-2379-1591↗
  7. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  8. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  9. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal a… Co-author DOI 10.1038/s41467-022-32591-8↗
  10. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
  11. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1097/md.0000000000006544↗
  12. Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. Co-author DOI 10.3747/co.22.2300↗

Trials 3

  1. A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer Principal investigator NCT03167112↗
  2. A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy Principal investigator NCT00810953↗
  3. A Phase I Study of ECO-4601 in Patients With Advanced Cancer Principal investigator NCT00338026↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gerald Batist · 3 shared papers, 1 shared trial, 2006–2026 · strength 0.61
  2. Ravi Ramjeesingh · 3 shared papers, 2022–2026 · strength 0.54
  3. Mustapha Ali Tehfe · 3 shared papers, 2022–2026 · strength 0.54
  4. Sharlene Gill · 3 shared papers, 2022–2026 · strength 0.54
  5. Christina Kim · 3 shared papers, 2022–2026 · strength 0.54
  6. James Thomas Topham · 3 shared papers, 2022–2026 · strength 0.54
  7. Félix Couture · 3 shared papers, 2022–2026 · strength 0.54
  8. Derek J. Jonker · 3 shared papers, 2022–2026 · strength 0.54
  9. Jennifer Jane Knox · 3 shared papers, 2022–2026 · strength 0.54
  10. David F. Schaeffer · 3 shared papers, 2022–2026 · strength 0.54
  11. Daniel John Renouf · 3 shared papers, 2022–2026 · strength 0.54
  12. Chris J. O’Callaghan · 3 shared papers, 2022–2026 · strength 0.54
  13. Joanna M. Karasinska · 2 shared papers, 2026 · strength 0.42
  14. Daniel A. Saltzman · 1 shared paper, 2026 · strength 0.33
  15. Yoo‐Joung Ko · 2 shared papers, 2022–2026 · strength 0.33
  16. Akmal Ghafoor · 1 shared paper, 2025 · strength 0.25
  17. Rachel Anne Goodwin · 1 shared paper, 2025 · strength 0.25
  18. Karen E. Mulder · 1 shared paper, 2025 · strength 0.25
  19. Joanna Gotfrit · 1 shared paper, 2025 · strength 0.25
  20. Shahid Ahmed · 1 shared paper, 2025 · strength 0.25
  21. Steve Gallinger · 2 shared papers, 2015–2026 · strength 0.24
  22. George Zogopoulos · 2 shared papers, 2015–2026 · strength 0.24
  23. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22
  24. Noelle K. LoConte · 1 shared paper, 2026 · strength 0.22
  25. Anne Ploquin · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.